Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Omar Alzarkali, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2025-3393

Published: 2025

Journal Articles

Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes

Julie Braish, Najla Al Ali, Zena Komrokji, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 240.

https://doi.org/10.1182/blood-2025-240

Published: 2025

Journal Articles

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Blood (2025) 146 (Supplement 1): 239.

https://doi.org/10.1182/blood-2025-239

Published: 2025

Journal Articles

Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA)

Rong Wang, Jessica Stempel, Rory Shallis, Jan Philipp Bewersdorf, Lourdes Mendez, Maximilian Stahl, Amer Zeidan, Xiaomei Ma, Nikolai Podoltsev

Blood (2025) 146 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2025-6393

Published: 2025

Journal Articles

Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States

Jessica Stempel, Rong Wang, Rory Shallis, Lourdes Mendez, Jan Philipp Bewersdorf, Maximilian Stahl, Amer Zeidan, Xiaomei Ma, Nikolai Podoltsev

Blood (2025) 146 (Supplement 1): 6392.

https://doi.org/10.1182/blood-2025-6392

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Kendra Sweet, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3856.

https://doi.org/10.1182/blood-2025-3856

Published: 2025

Journal Articles

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Rami Komrokji, Najla Al Ali, Zena Komrokji, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Kendra Sweet, Jeffrey Lancet, Eric Padron, David Sallman

Blood (2025) 146 (Supplement 1): 2072.

https://doi.org/10.1182/blood-2025-2072

Published: 2025

Journal Articles

Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study

Alexandra Gomez-Arteaga, Rory Shallis, Mariam Nawas, Landi Guo, Temitope Oloyede, Kwang Woo Ahn, Veronika Bachanova, Michael Byrne, Sergio Giralt, Lohith Gowda, Ann Jakubowski, Mark Litzow, Filippo Milano, Kristin Page, Wael Saber, Nelli Bejanyan, Larisa Broglie, Xinjie Xu, Jean Yared

Blood (2025) 146 (Supplement 1): 1060.

https://doi.org/10.1182/blood-2025-1060

Published: 2025

Journal Articles

Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study

Blood (2025) 146 (Supplement 1): 874.

https://doi.org/10.1182/blood-2025-874

Published: 2025

Journal Articles

Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia (AML)

Utsav Joshi, Fatima Tuz Zahra, Pujan Patel, Najla Al Ali, Zachary Thompson, Nagehan Pakasticali, Jinming Song, Rory Shallis, Zhuoer Xie, Seongseok Yun, Andrew Kuykendall, Eric Padron, Alison Walker, David Sallman, Rami Komrokji, Jeffrey Lancet, Mohammad Hussaini, Onyee Chan

Blood (2025) 146 (Supplement 1): 4630.

https://doi.org/10.1182/blood-2025-4630

Published: 2025

Journal Articles

Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability

Umar Iqbal, Onyee Chan, Rory Shallis, Lorena Lopez-Gonzalez, Syeda Saba Kareem, Alison Walker, Craig Freyer, Andrew Kuykendall, Huan Huang, Zhuoer Xie, Eric Padron, Rami Komrokji, Jeffrey Lancet, David Sallman

Blood (2025) 146 (Supplement 1): 3448.

https://doi.org/10.1182/blood-2025-3448

Published: 2025

Journal Articles

Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)

Fatima Tuz Zahra, Ekrem Turk, Najla Al Ali, Sean Haney, Dimitrios Drekolias, Nicole Vincelette, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Eric Padron, Alison Walker, David Sallman, Rami Komrokji, Jeffrey Lancet, Seongseok Yun, Onyee Chan

Blood (2025) 146 (Supplement 1): 291.

https://doi.org/10.1182/blood-2025-291

Published: 2025

Journal Articles

Clinical, cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia (APL): Real-world analysis

Aram Bidikian, Amer Al-Musa, Cameron Hunter, Lourdes Mendez, Nikolai Podoltsev, Maximilian Stahl, Amer Zeidan, Rory Shallis, Jan Philipp Bewersdorf

Blood (2025) 146 (Supplement 1): 5160.

https://doi.org/10.1182/blood-2025-5160

Published: 2025

Journal Articles

Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy

Blood (2025) 146 (Supplement 1): 4291.

https://doi.org/10.1182/blood-2025-4291

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies

Fnu Amisha, Jessica Shostak, Wenyi Fan, Onyee Chan, Rory Shallis, Zhuoer Xie, Alison Walker, Sameh Gaballa, Javier Pinilla-Ibarz, Eric Padron, David Sallman, Bijal Shah, Julio Chavez, Rami Komrokji, Jeffrey Lancet, Mohammad Hussaini, Yumeng Zhang, Todd Knepper, Andrew Kuykendall

Blood (2025) 146 (Supplement 1): 3531.

https://doi.org/10.1182/blood-2025-3531

Published: 2025

Journal Articles

Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy

Cameron Hunter, Karthik Chetlapalli, Satoko Ito, Jan Philipp Bewersdorf, Prajwal Boddu, Sabrina Browning, Stephanie Halene, Terri Parker, Scott Huntington, Shalin Kothari, Lourdes Mendez, Natalia Neparidze, Tarsheen Sethi, Maximilian Stahl, Nikolai Podoltsev, Amer Zeidan, Rory Shallis, George Goshua

Blood (2025) 146 (Supplement 1): 6208.

https://doi.org/10.1182/blood-2025-6208

Published: 2025

Journal Articles

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2025-1726

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes

Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes

Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA)

Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study

Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study

Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia (AML)

Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability

Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)

Clinical, cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia (APL): Real-world analysis

Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies

Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only